R and R Eye Research LLC

1. Oyster Point Pharma, Inc. $630,277 17 payments
2. AbbVie, Inc. $291,526 24 payments
3. Sun Pharmaceutical Industries Inc. $38,794 10 payments
4. Johnson & Johnson Surgical Vision, Inc. $27,600 9 payments
5. RxSight Inc $22,000 5 payments
6. Shire North American Group Inc $10,103 4 payments
7. Ivantis, Inc $3,180 1 payment
8. Takeda Pharmaceuticals U.S.A., Inc. $869 1 payment

1. A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis $566,909 13 payments
2. Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). $120,016 2 payments
3. A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (Virgo) $68,150 4 payments
4. Phase 1x2F2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia $59,624 2 payments
5. A Phase 2, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of Oc-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (The Olympia Study) $50,244 2 payments
6. Clinical Evaluation of the Vision Performance of Tecnis Eyhance Intraocular Lenses with Tecnic Simplicity as Compared to Tecnis 1-Piece Intraocular Lenses $27,600 9 payments
7. Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma $26,284 9 payments
8. A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery $23,043 5 payments
9. Pmcs-010 $22,000 5 payments
10. A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis $15,751 5 payments

1. Other $38,794 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.